


04-11-02

CPA/1600 \$

By Express Mail # EV02804195US



Attorney Docket # 4271-29P/CPA

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Continued Prosecution Application of

Thomas STRÜNGMANN

Serial No.: 09/674,800

Filed: November 06, 2000

For: Transdermal Therapeutic System for the  
Administration of Candesartan

Check box if applicable:

☐ DUPLICATE**BOX CPA**

RECEIVED  
APR 15 2002  
TECH CENTER 1600/2900

7/Reg under  
1.53(d)

**CONTINUED PROSECUTION APPLICATION (CPA)  
REQUEST TRANSMITTAL**

*Submit an original and a duplicate for fee processing  
(Only for Continuation or Divisional applications under 37 C.F.R. §1.53(d))*

Ref  
4-26-02

Assistant Commissioner for Patents

**BOX CPA**

Washington, DC 20231

Sir:

This is a request for filing a Continuation application under 37 C.F.R. §1.53(d), of prior application number **09/674,800** filed on **November 06, 2000**, entitled **Transdermal Therapeutic System for the Administration of Candesartan**.

1. ☒ Utilize the file jacket and contents of the prior application, including the specification, drawings and oath or declaration from the prior application, to constitute this new application, and assign the application number of the prior application to this application for identification purposes.
2. ☒ The filing of this CPA is a request to expressly abandon the prior application as of the filing date of the request for this CPA.
3. ☐ Enter the amendment previously filed on under 37 C.F.R. §1.116 in the prior nonprovisional application.
4. ☒ A preliminary amendment is enclosed.

04/12/2002 AWONDAF1 00000161 09674800

01 FC:131

740.00 OP

**BEST AVAILABLE COPY**

5. ☐ This application is filed by fewer than all the inventors named in the prior application, 37 C.F.R. §1.53(d)(4).
- a. ☐ Delete the following inventor(s) named in the prior nonprovisional application: \_
- b. ☐ The inventor(s) to be deleted are set forth on a separate sheet attached hereto.
6. ☐ A new power of attorney or authorization of agent (PTO/SB/81) is enclosed.
7. ☐ Information Disclosure Statement (IDS) is enclosed:
- a. ☐ PTO-1449
- b. ☐ Copies of IDS Citations
8. A fee computation sheet for this application is attached hereto.
- a. ☒ A check for \$740 to cover the filing fee is enclosed.
- b. ☐ Please charge our Deposit Account No. 03-2412 in the amount of \$. A duplicate copy of this paper is enclosed.
9. ☒ For this continuing application and the parent application the Commissioner is hereby authorized to charge payment of the following fees, or to credit any overpayment, to Deposit Account No. 03-2412. A duplicate copy of this paper is enclosed.
- ☒ Any additional filing fees required under 37 CFR §1.16.
- ☒ Any patent application processing fees under 37 CFR §1.17 not otherwise paid by check.
10. ☒ A petition for a ☐ one ☐ two ☒ three month extension of time to maintain the pendency of the prior application is enclosed herewith, together with a check for \$920 in payment of the government fee for said extension of time.
11. Small entity status:
- a. ☐ Small entity statement is claimed.
- b. ☐ is no longer claimed.
12. ☒ The prior application's correspondence address will carry over to this CPA UNLESS a new correspondence address is provided below.
- ☐ New correspondence address:

Vincent M. Fazzari, Esq.  
Cohen, Pontani, Lieberman & Pavane  
551 Fifth Avenue, Suite 1210  
New York, New York 10176  
Telephone: (212) 687-2770  
Facsimile: (212) 972-5487


**BEST AVAILABLE COPY**

13. ☒ The undersigned declares that all statements made herein of his or her own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false

By Express Mail # EV028042495US


statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Respectfully submitted,  
COHEN, PONTANI, LIEBERMAN & PAVANE

By   
\_\_\_\_\_  
Vincent M. Fazzari  
Reg. No. 26,879  
551 Fifth Avenue, Suite 1210  
New York, New York 10176  
(212) 687-2770

Dated: April 10, 2002

**BEST AVAILABLE COPY**



Attorney Docket # 4271-29P/CPA

By Express Mail # EV028042495US

TECH CENTER 1600/2900

RECEIVED  
APR 15 2002

Patent  
Bet  
4-26-02

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Continued Prosecution Application of

Thomas STRÜNGMANN et al.

Serial No.: 09/674,800

Filed: November 06, 2000

For: Transdermal Therapeutic System for the  
Administration of Candesartan

PRELIMINARY AMENDMENT

Assistant Commissioner for Patents  
Washington, D.C. 20231

BEST AVAILABLE COPY

S I R:

Prior to examination of the above-identified application please amend the application as follows:

In the Specification:

On Page 1, please insert the following:

--CROSS-REFERENCE TO RELATED APPLICATION(S)

B<sup>1</sup>  
This application is a Continuation of U.S. Patent Application Serial No. 09/674,800, filed November 06, 2000, which claims priority from Applications filed in Germany on May 6, 1998, No. 198 20 151.6 on May 4, 1999, No. PCT/EP 99/03029, respectively.